GEN Exclusives

More »

GEN News Highlights

More »
Apr 23, 2008

CDC Commissions Acambis for $425M to Supply Smallpox Vaccine

  • Acambis won a $425 million, 10-year contract with the CDC to provide warm-base manufacturing capability for the ACAM2000 smallpox vaccine. If the CDC purchases more doses of the vaccine than the minimum, Acambis could make up $660 million.

    Acambis will establish a U.S.-based manufacturing capability for the vaccine, deliver against CDC orders for a minimum of 9 million doses per annum for the last eight years of the contract, and undertake activities to maintain its product licence. The CDC may purchase up to 39 million doses in the last six contract years if necessary, which would increase the value of the contract to some $660 million.

    Acambis will transfer the entire ACAM2000 production process to its facilities in Canton, MA, and Rockville, MD.
    ACAM 2000 was developed under a contract with the CDC, and over 195 million doses of the vaccine have been delivered to the CDC for the strategic national stockpile.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »